Skip to content
CFPS Research Archives

Ecnoglutide

Human clinical Weight Loss & Metabolism 3 sources

Ecnoglutide (XW003) is a novel, long-acting, cAMP-signaling biased GLP-1 receptor agonist. It is currently in late-stage clinical development for the treatment of type 2 diabetes and obesity, demonstrating significant improvements in glycemic control and substantial weight loss.

01Dosing reference

Amount
0.4 mg to 2.4 mg (investigational)
Frequency
Once weekly
Cycle
Continuous use with gradual dose titration over several weeks
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

GLP-1 Receptor Activation

Ecnoglutide selectively binds to and activates the GLP-1 receptor, utilizing a biased signaling mechanism that favors cAMP production.

02

Incretin Effect and Gastric Delay

It stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, which increases feelings of fullness.

03

Metabolic Optimization

These actions lead to improved blood glucose levels and significant reductions in body weight and adiposity.

03Human evidence

In Phase 3 trials for type 2 diabetes, ecnoglutide significantly reduced HbA1c levels and body weight compared to placebo and active comparators.

Randomized, double-blind, placebo-controlled trials in adults with inadequately controlled type 2 diabetes.

Phase 2/3 obesity trials demonstrated substantial, dose-dependent weight loss over 26 to 52 weeks of treatment.

Conducted in adults with obesity or overweight with at least one weight-related comorbidity.

04Preclinical evidence

Ecnoglutide showed potent GLP-1 receptor activation with biased signaling, leading to enhanced efficacy in animal models of diabetes.

In vitro receptor assays and rodent models of type 2 diabetes.

Pharmacokinetic studies in non-human primates demonstrated an extended half-life suitable for once-weekly dosing.

Preclinical pharmacokinetic and pharmacodynamic profiling in cynomolgus monkeys.

05What is known vs. unknown

Reasonably established
  • Ecnoglutide is a long-acting GLP-1 receptor agonist designed for once-weekly subcutaneous injection.
  • It utilizes biased signaling at the GLP-1 receptor, which may offer a differentiated efficacy and tolerability profile.
  • Clinical trials have shown it to be highly effective for both glycemic control in type 2 diabetes and weight management in obesity.
  • Its side effect profile is consistent with the GLP-1 RA class, primarily involving transient gastrointestinal symptoms.
Unknowns & limits
  • Long-term cardiovascular outcomes and safety data are not yet fully established, as cardiovascular outcome trials are ongoing or pending.
  • Direct head-to-head comparisons with newer dual (GIP/GLP-1) or triple agonists in large-scale Phase 3 trials are currently limited.

06Safety & regulatory context

Regulatory statusEcnoglutide is currently an investigational drug and has not yet received FDA approval. Its safety profile is consistent with other GLP-1 receptor agonists, with the most common adverse events being gastrointestinal in nature, such as nausea, vomiting, diarrhea, and decreased appetite. These side effects are typically mild to moderate and occur most frequently during the dose-escalation phase. Like other GLP-1 RAs, it is expected to carry warnings regarding the potential risk of medullary thyroid carcinoma (MTC) and is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

07Compared with Semaglutide

Ecnoglutide vs. Semaglutide
Key difference
While both are once-weekly GLP-1 receptor agonists, ecnoglutide is engineered with a cAMP-signaling biased mechanism that may potentially optimize the balance between efficacy and gastrointestinal tolerability.
When researchers discuss each
Semaglutide is discussed as the established, FDA-approved gold standard for GLP-1-mediated weight loss and diabetes management, whereas ecnoglutide is discussed as a promising next-generation investigational alternative in late-stage clinical trials.

08Glossary

GLP-1 Receptor Agonist
A class of medications that mimic the natural incretin hormone GLP-1 to increase insulin secretion, decrease glucagon, and promote satiety.
Biased Signaling
A pharmacological concept where a drug preferentially activates one specific intracellular signaling pathway over others when binding to a receptor, potentially improving efficacy or reducing side effects.
HbA1c
Glycated hemoglobin, a blood test that measures average blood sugar levels over the past two to three months.

09Knowledge check

Q1What is the primary mechanism of action of ecnoglutide?
Q2Based on its pharmacokinetic profile, how often is ecnoglutide typically administered in clinical trials?
Q3Which limitation of the current evidence for ecnoglutide is explicitly noted in the dossier?
Q4How does the dossier characterize the key difference between ecnoglutide and semaglutide?
Q5Which safety or regulatory statement about ecnoglutide is supported by the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism
Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism
Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism
Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.